Dulaglutide (marketed as Trulicity®) is a once-weekly glucagon-like peptide-1 (GLP-1) receptor agonist developed by Eli Lilly for the treatment of type 2 diabetes. As a long-acting GLP-1 analog, dulaglutide has shown neuroprotective potential in preclinical models of Parkinson's disease and Alzheimer's disease, though clinical evidence in neurodegeneration is more limited compared to other GLP-1 agonists like exenatide and liraglutide .
Dulaglutide is a fused peptide consisting of two modified human GLP-1 molecules linked to an Fc fragment of human IgG4. This design provides several advantages:
- Once-weekly dosing: Enhanced patient adherence
- Long half-life: Approximately 4.7 days
- Steady-state exposure: More consistent drug levels
- Reduced immunogenicity: Fc fusion reduces antibody formation
While originally developed for glycemic control in type 2 diabetes, dulaglutide's effects on insulin signaling, neuroinflammation, and neuronal survival have generated interest in its potential for neurodegenerative diseases.
Dulaglutide activates GLP-1 receptors (GLP-1R) expressed throughout the central nervous system, though its brain penetration is considered moderate compared to other GLP-1 agonists :
| Brain Region |
GLP-1R Expression |
Functional Implications |
| Hypothalamus |
High |
Metabolic regulation, energy homeostasis |
| Hippocampus |
High |
Memory formation, synaptic plasticity |
| Cortex |
Moderate |
Cognitive processing |
| Cerebellum |
Low-Moderate |
Motor coordination |
Upon GLP-1R activation by dulaglutide, multiple neuroprotective signaling cascades are engaged:
Dulaglutide
|
v
GLP-1 Receptor Activation
|
+---> cAMP/PKA/CREB ----> BDNF expression, gene transcription
|
+---> PI3K/Akt Pathway ----> Neuronal survival, anti-apoptotic
|
+---> ERK1/2 MAPK ----> Synaptic plasticity, LTP
|
+---> mTOR Pathway ----> Protein synthesis, autophagy
|
+---> NF-kB Inhibition ----> Anti-inflammatory effects
-
Anti-apoptotic Effects
- Akt-mediated phosphorylation of BAD
- Caspase-3 inhibition
- Preservation of mitochondrial integrity
-
Anti-inflammatory Effects
- Reduced microglial activation
- Decreased pro-inflammatory cytokines (TNF-α, IL-1β, IL-6)
- NF-κB pathway inhibition
-
Metabolic Benefits
- Enhanced insulin sensitivity
- Improved cerebral glucose metabolism
- Reduced oxidative stress
-
Synaptic Protection
- Promotion of dendritic spine density
- Enhancement of long-term potentiation (LTP)
- Protection against excitotoxicity
-
Autophagy Enhancement
- mTOR-dependent autophagy activation
- Improved clearance of pathological proteins
- Reduced amyloid-beta production in APP transgenic mice
- Decreased tau hyperphosphorylation
- Improved performance in Morris water maze
- Reduced neuroinflammation markers
- Protected dopaminergic neurons in MPTP models
- Reduced alpha-synuclein aggregation
- Improved motor function in 6-OHDA lesioned rats
- Enhanced mitochondrial function
- Fewer preclinical studies compared to exenatide and liraglutide
- Moderate brain penetration may limit efficacy
- Limited data on long-term neuroprotection
The GIVE (GLP-1 Infusion for Vascular Events) Phase II trial evaluated dulaglutide in early Alzheimer's disease patients:
| Parameter |
Details |
| Design |
Randomized, double-blind, placebo-controlled |
| Patients |
~100 with early AD |
| Dose |
1.5 mg weekly |
| Duration |
12 months |
| Primary Outcome |
Cerebral glucose metabolism (FDG-PET) |
Status: Completed 2023, results pending full publication.
- No large-scale PD trials of dulaglutide specifically
- Observational studies in diabetic patients suggest potential benefit
- Interest in combination with other GLP-1 agonists
| Trial |
Phase |
Status |
Focus |
| GIVE-AD |
Phase II |
Completed |
Brain metabolism |
| Observational PD |
N/A |
Ongoing |
Real-world data |
Gastrointestinal effects are the most common:
| Side Effect |
Frequency |
Management |
| Nausea |
10-20% |
Start low, titrate slowly |
| Diarrhea |
5-10% |
Usually transient |
| Abdominal pain |
3-8% |
Usually transient |
| Decreased appetite |
3-5% |
Often improves over time |
- Pancreatitis: Rare but documented; contraindicated in patients with history
- Thyroid C-Cell Tumors: Boxed warning; contraindicated in MEN2
- Hypoglycemia: Low risk as monotherapy
- Renal Impairment: Use with caution in severe renal disease
- GI Adverse Events: Higher risk in patients with gastroparesis
- Once-weekly dosing: Improved adherence
- Established safety: Extensive clinical use in diabetes since 2014
- Steady-state levels: Consistent exposure
- Well-characterized PK/PD: Clear profile
- Off-label available: Can be prescribed for neurodegenerative indications
¶ Dosing and Administration
| Phase |
Dose |
Duration |
Notes |
| Initiation |
0.75 mg weekly |
4 weeks |
Tolerance assessment |
| Maintenance |
1.5 mg weekly |
Ongoing |
Standard dose |
| Escalation |
3.0 mg weekly |
If tolerated |
Higher tier dose |
- Route: Subcutaneous injection
- Sites: Abdomen, thigh, upper arm
- Time: Same time each week, with or without food
- Storage: Refrigerate; stable at room temperature for 14 days
Dulaglutide is not FDA-approved for neurodegenerative diseases but can be prescribed off-label:
- Prescribing: Available through standard prescription
- Insurance: May not cover for neurodegenerative indications
- Cost: Brand-name only (generic not available)
- Monitoring: Regular follow-up recommended
| Drug |
Half-life |
Dosing |
Brain Penetration |
PD Trials |
AD Trials |
| Dulaglutide |
4.7 days |
Weekly |
Moderate |
Limited |
Phase II |
| Exenatide |
2.4 days |
Weekly |
Low-Moderate |
Phase III |
Phase II |
| Liraglutide |
13 hours |
Daily |
Moderate |
Phase II |
Phase II |
| Semaglutide |
7 days |
Weekly |
High |
Phase II |
Phase III |
- Dosing Frequency: Dulaglutide offers once-weekly administration, improving adherence over daily liraglutide
- Brain Penetration: Semaglutide has the highest brain penetration; dulaglutide is moderate
- Clinical Data: Less clinical data in neurodegeneration than exenatide or liraglutide
- Molecular Size: Larger molecular size (Fc fusion) may affect BBB penetration
While dulaglutide has not been specifically studied in corticobasal syndrome (CBS) or progressive supranuclear palsy (PSP), mechanistic considerations suggest potential relevance:
-
Tau-Targeting Mechanisms: Both CBS and PSP are 4R-tauopathies
- May reduce tau hyperphosphorylation via GSK-3β modulation
- Autophagy enhancement could promote tau clearance
- Synaptic protection preserves neuronal connectivity
-
Neuroinflammation Modulation
- Microglial suppression in affected regions
- Cytokine reduction (TNF-α, IL-1β, IL-6)
- NF-κB pathway inhibition
-
Metabolic Benefits
- Cerebral insulin signaling improvement
- Enhanced glucose uptake in affected brain regions
- Protection against metabolic contributions to neurodegeneration
-
Once-Weekly Advantage
- Consistent drug exposure
- Improved patient adherence in chronic conditions
- Potential for better CNS accumulation
- No CBS/PSP-specific trials of dulaglutide to date
- Limited preclinical data specific to tauopathies
- GIVE-AD trial may provide relevant biomarker data
- Off-label use has been considered by some clinicians
- Clinical trials: Randomized controlled trials in CBS and PSP populations
- Biomarker studies: CSF tau, neurofilament light chain as outcome markers
- Neuroimaging: PET for tau burden, metabolic imaging
- Combination approaches: GLP-1 agonists with anti-tau therapies
¶ With Standard PD Medications
Dulaglutide can potentially be combined with standard Parkinson's disease treatments:
- Levodopa: Different mechanisms; potential synergy
- Dopamine agonists: Additive effects possible
- MAO-B inhibitors: No known interactions
- COMT inhibitors: No known interactions
- Physical Exercise: Synergistic effects on neuroplasticity
- Metformin: Enhanced metabolic benefits
- Neuroinflammation modulators: Complementary mechanisms
- Anti-amyloid therapies: Different targets
- Not typically combined with other GLP-1 agonists
- May consider sequential therapy
- Interest in dual/triple agonists (GIP/GLP-1/Glucagon)
- GIVE-AD Trial Results: Full publication expected
- Observational Studies: Real-world effectiveness data
- Biomarker Studies: CSF and imaging biomarkers
- Oral Dulaglutide: Under development
- Fixed-Dose Combinations: With other metabolic agents
- Longer-Acting Formulations: For improved CNS exposure
Dulaglutide as a single GLP-1 agonist may be superseded by:
- Tirzepatide: GIP/GLP-1 dual agonist
- Retatrutide: GIP/GLP-1/Glucagon triple agonist
These multi-agonists show enhanced neuroprotective effects in preclinical models.